Health Technology Holding (HTH)

SOM Biotech is a late clinical-stage biopharmaceutical company focused on discovering and developing new impactful treatments for rare diseases of the CNS using an AI-driven platform for drug discovery.

Neurofenix is a tech-enabled virtual care provider that helps neurological patients achieve their rehabilitation goals at home through personalized, engaging, and evidence-based therapy programs.

SeaBeLife is a biotechnology company developing innovative small molecules that simultaneously target two major regulated cell death pathways - necroptosis and ferroptosis - designed to address major unmet medical needs in acute, rare and chronic indications.

Hyivy Health is a woman-owned company focused on pelvic health rehabilitation, providing innovative solutions for patients and clinicians. Their mission is to improve the standard of care for pelvic health issues through holistic, patient-centered approaches and advanced technology.

Endostart is a startup focused on the development and manufacturing of a new generation of medical devices for gastrointestinal endoscopy, utilizing innovative Magnetic Balloon Technology.

EpilepsyGTx is a late preclinical-stage biotech developing cutting-edge gene therapies that will transform the management of focal refractory epilepsy (FRE).

Leuko is developing PointCheck™, the first device for non-invasive white blood cell monitoring. This portable device allows for fast and simple assessment of white blood cell levels without the need for blood draws, aiming to improve the quality of life for immunosuppressed patients.

Lys Therapeutics is a biotechnology company developing first-in-class monoclonal antibodies to treat patients suffering from neurodegenerative and neurovascular diseases with high unmet medical needs.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.

Early-stage investor spanning service-heavy care delivery and deep neuro/bio/AR frontier tech. Arkitekt Ventures deliberately spans both service-heavy care delivery companies and deep frontier neuro/bio/AR technologies, reflecting a thesis that the future of care sits at the intersection of physical clinics and bleeding-edge tech. The fund shows an unusually high concentration in brain- and nervous-system related innovation, suggesting a distinctive neuro + AI + delivery wedge inside healthtech.

Solo-GP venture capital fund founded and managed entirely by Dr. Ling Wong, an MIT-trained chemical engineer and biologist with a Harvard PhD who invented the world's first inhaled tuberculosis vaccine. The fund writes checks from $500K to $50M across seed through growth stages, backing breakout companies like Slack (acquired by Salesforce for $27.7B), Guardant Health (IPO), and Anacor (acquired by Pfizer for $5.2B) while co-investing alongside top-tier firms like Andreessen Horowitz and Sequoia.